ArticleJMIR research protocols2025
Sustained Virological Response as a Surrogate Marker for Mortality, Decompensated Cirrhosis, or Hepatocellular Carcinoma in People With Chronic Hepatitis C Virus Infection Treated With Direct-Acting Antivirals: Protocol for a Bayesian and Causal Mediation Analysis.
Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies.Systematic reviews · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSustained virological response (SVR) is commonly used as a marker of treatment success in people with chronic hepatitis C virus (HCV) infection. However, there is uncertainty on whether SVR is a validated surrogate marker of successful chronic HCV infection treatment.
objectiveThis research project aims to evaluate whether SVR is a good surrogate for all-cause mortality, decompensated cirrhosis, any specific aspect of liver decompensation (jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome, or variceal hemorrhage), or hepatocellular carcinoma in people with chronic HCV infection eligible to receive direct-acting antiviral drugs.
methodsWe will use two ongoing systematic reviews on the effectiveness of direct-acting antiviral drugs in chronic HCV infection as our data sources. The analysis plan is to estimate the regression coefficients or between-studies correlation between SVR and an event using three different Bayesian approaches with OpenBUGS, as outlined in the guidance by the evidence synthesis unit, and estimate the average proportion of the effect mediated through SVR by causal mediation analysis using R.
resultsAs of June 19, 2025, the two systematic reviews (one on randomized clinical trials and one on observational studies) on the effectiveness of direct-acting antiviral drugs in chronic HCV infection are ongoing.
conclusionsWe will use the German Institute of Quality and Efficiency in Health Care criterion for surrogacy for cancer, with at least 50% of the treatment effect mediated through SVR, but the information will be reported in a way that allows people to interpret the information using their own criteria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.